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Matrix metalloproteinase 13 (MMP-13) degrades collagenous extracellular matrix and its aberrant activity
associates with diseases such as arthritis, cancer, atherosclerosis and fibrosis. The wide range of MMP-13
proteolytic capacity suggests that it is a powerful, potentially destructive proteinase and thus it has been
believed that MMP-13 is not produced in most adult human tissues in the steady state. Present study has
revealed that human chondrocytes isolated from healthy adults constitutively express and secrete MMP-13,
but that it is rapidly endocytosed and degraded by chondrocytes. Both pro- and activated MMP-13 bind to
clusters II and III of low-density lipoprotein (LDL) receptor-related protein 1 (LRP1). Domain deletion studies
indicated that the hemopexin domain is responsible for this interaction. Binding competition between MMP-13
and ADAMTS-4, -5 or TIMP-3, which also bind to cluster II, further shown that the MMP-13 binding site within
cluster II is different from those of ADAMTS-4, -5 or TIMP-3. MMP-13 is therefore co-endocytosed with
ADAMTS-5 and TIMP-3 by human chondrocytes. These findings indicate that MMP-13 may play a role on
physiological turnover of cartilage extracellular matrix and that LRP1 is a key modulator of extracellular levels
of MMP-13 and its internalization is independent of the levels of ADAMTS-4, -5 and TIMP-3.© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Thematrixmetalloproteinases (MMPs)area familyof
zinc-dependent proteolytic enzymes that have the
capacity to degrade many protein components of the
extracellular matrix (ECM). Their activities are consid-
ered to have important roles in ECM turnover during
embryogenesis, morphogenesis, normal tissue remod-
elling and repair, but uncontrolled activities contribute to
pathogenesis of diverse diseases associated with theAuthors. Published by Elsevier B.V. This
nses/by/4.0/).tissue destruction, such as arthritis, cardiovascular
disease, cancer, chronic ulcers and fibrosis [1–7].
MMP-13 (collagenase 3) belongs to the collagenase
subgroup of the MMP family because of its structural
similarity to MMP-1 (collagenase 1) and its ability to
cleave interstitial fibrillar collagens. It was originally
cloned from human breast cancer tissue [8]. It is
produced and secreted from many cell types as a
60-kDa precursor form (proMMP-13), which can be
activated to a48-kDa form viaa50-kDa intermediate byis an open access article under the CC BY license (http://
Matrix Biol. (2016) 56, 57–73
58 Molecular basis behind MMP-13 endocytosisplasmin, MMP-2, MMP-3 and MMP-14 [9,10]. In
addition to fibrillar collagen types I, II and III, MMP-13
cleaves other ECM molecules such as N-terminal
non-helical telopeptides of type I collagen [11], gelatins
[9], type IV, IX, X, and XIV collagens, large tenascin C,
fibronectin [12], aggrecan [13], perlecan [14], fibrillin-1
[15], and osteonectin [16]. The enzyme plays a role in
ECM remodelling during foetal bone development [17],
post-natal bone remodelling [18], and gingival and
foetal skin wound repair [19,20]. Mice lacking the
MMP-13 gene exhibit delayed formation of long bones,
further providing evidence for the importance of the
enzyme in skeletal development [21,22]. The enzyme
is also considered as a major collagenase in the
development of osteoarthritis (OA) because of its
elevated expression in human OA cartilage and its
effective ability to degrade collagen II fibrils [9,23,24].
Further support for this is a study with MMP-13-null
mice, whose cartilage was protected from degradation
in the surgically induced OA model [25]. The wide
range ofMMP-13 proteolytic capacity suggests that it is
a powerful, potentially destructive proteinase, and
therefore its activity needs to be strictly controlled
under normal physiological conditions.
The activity of MMP-13 can be regulated at
multiple levels, which include transcriptional regula-
tion [26], epigenetic modification [27], post-transcrip-
tional regulation by microRNAs [28–30], activation of
pro-enzymes [9,10] and inhibition by endogenous
inhibitors [9,10]. In addition, Partridge and co--
workers have shown that rat MMP-13 is endocy-
tosed and degraded by osteoblastic cells [31] and
this requires a two-step processes, involving a first
binding to a 170 kDa cell surface receptor with a
high-affinity and it is subsequently endocytosed
through low-density lipoprotein (LDL) receptor-re-
lated protein 1 (LRP1) [32,33]. However, Bailey et al.
[34] reported that the human orthologue of the
170-kDa receptor, Endo180, did not bind to MMP-13
and therefore molecular mechanism behind MMP-13
endocytosis remains to be elucidated.
LRP1 is a type I transmembrane cell surface
receptor consisting of a 515-kDa α-chain containing
the extracellular ligand-binding domains and a
non-covalently associated 85-kDa β-chain contain-
ing a transmembrane domain and a cytoplasmic tail.
Both chains are derived from a single chain of
~600 kDa that is processed by furin during the
secretory process. LRP1 is widely expressed [35,36]
and internalizes more than 40 ligands from the
extracellular environment, including lipoproteins,
ECM proteins, growth factors, cell surface receptors,
proteinases, proteinase inhibitors and proteinase--
proteinase inhibitor complexes [37,38]. The ablation
of the LRP1 gene in mice is embryonically lethal
[39], but tissue specific deletion of the LRP1 gene
has demonstrated that it protects the vasculature
homeostasis and controls β-amyloid precursor pro-
tein trafficking, lipid metabolism in adipocytes, andmacrophage biology [37]. In cartilage, LRP1 can
endocytose the two major aggrecanases
ADAMTS-4 [40] and ADAMTS-5 [41] and tissue
inhibitor of metalloproteinases (TIMP)-3, an endog-
enous inhibitor of collagenases and aggrecanases
[42,43]. LRP1 interacts with frizzled-1 and down--
regulates the canonical Wnt-β-catenin signalling
pathway [44]. It also represses the hypertrophy of
chondrocytes during endochondral ossification by
removing connective tissue growth factor (CCN-2)
[45,46]. LRP1 is, therefore, an important regulator of
skeletal development and maintenance of cartilage
homeostasis. Given that MMP-13 plays a key role
on ECM remodelling in skeletal development, its
endocytosis must be an important for the regulation
of proteinase activity and cartilage homeostasis.
In this study, we investigated the molecular
mechanism of MMP-13 endocytosis by human
normal chondrocytes. We found that human chon-
drocytes constitutively express and secrete
MMP-13, but its extracellular level is downregulated
by LRP1-mediated endocytosis. We also show here
that MMP-13 directly binds to LRP1 via its hemo-
pexin (Hpx) domain (HpxMMP-13) and its binding
clusters in LRP1 have been determined. Competi-
tion studies between MMP-13 and ADAMTS-4, -5
and TIMP-3 further revealed the selectivity of its
interaction with LRP1 and the co-endocytosis of
MMP-13 with ADAMTS-4, -5 or TIMP-3.2. Results
2.1. MMP-13 is constitutively expressed, secreted
and endocytosed by human normal chondrocytes
We first investigated the production of endoge-
nous MMP-13 in human chondrocytes isolated
from healthy adults. Endogenous MMP-13 was
not detectable by Western blotting in the condi-
tioned medium or the cell lysate of human chon-
drocytes even after 8-h incubation in the absence of
receptor-associated protein (RAP), a ligand-bind-
ing antagonist for the LDL receptor family (Fig. 1A).
On the other hand, endogenous proMMP-13 was
detected in the medium but not in the cell lysate in
the presence of RAP and the amount was
increased over 8 h (Fig. 1A). Semi-quantitative
analysis of immune-reactive bands showed a linear
increase of proMMP-13 in media in the presence of
RAP over 8 h and that approx. 203–418 pg of
proMMP-13 (per 105 cells) accumulated in 8 h (Fig.
1B). We estimated approx. 2.0–4.2 × 10 4
proMMP-13 molecules were secreted by a single
chondrocyte in 8 h, but they were rapidly endocy-
tosed through the LDL receptor family-mediated
endocytosis. The quantitative mRNA analysis of
human chondrocytes after 2-h incubation in the
Fig. 1. MMP-13 is constitutively expressed, secreted and endocytosed by human normal chondrocytes. Human normal
chondrocytes (n = 3) were incubated in the absence or presence of 500 nM RAP for 0–8 h. A, Representative Western
blot image for endogenous MMP-13 in the medium and cell lysate detected using an MMP-13 specific antibody (H-230). B,
Densitometric analysis of immunoreactive proMMP-13 bands detected in A was carried out. The concentrations of
proMMP-13 in the medium were determined in comparison with purified proMMP-13 as described under “Experimental
procedures”. C, Results of TaqMan real-time PCR showing relative levels of mRNA for MMP-13 in human normal
chondrocytes incubated in the absence or presence of 500 nM RAP for 2 h. Points represent the means ±S.D (n = 3).
59Molecular basis behind MMP-13 endocytosispresence or absence of RAP showed similar levels
of MMP-13 mRNA (Fig. 1C).
2.2. LRP1 is the primary endocytic receptor for
MMP-13 in human normal chondrocytes
To investigate underlying molecular mechanism
of endocytic pathway of MMP-13 in human
chondrocytes, we first examined endocytosis of
exogenously added proMMP-13 (FLAG tag at
N-terminus) by immunofluorescent confocal
microscopy. The punctate staining of proMMP-13
was observed within cells, colocalizing with early
endosome antigen 1 (EEA1), a marker for early
endosomes (Fig. 2A). The intracellular fluorescent
signal for proMMP-13 was abolished in the pre-
sence of RAP. To investigate whether LRP1 is the
primaryreceptor for theendocytosisofproMMP-13,
siRNA-mediated gene silencing of LRP1 wascarried out. Silencing LRP1 in human normal
chondrocytes by LRP1-targeting siRNA reduced
levels of the 515-kDa extracellular α-chain and the
85-kDa β-chain containing the transmembrane
domain by 90 and 88%, respectively (Fig. 2B).
Cultured chondrocytes endocytosed proMMP-13
rapidly with half-life of approx. 70 min, whereas
cellular uptakeofproMMP-13wasalmost complete-
ly inhibited in LRP1-depleted cells (Fig. 2C). We
further investigated the role of LRP1 in the surface
binding of proMMP-13 by monitoring exogenously
addedproMMP-13 inculturemediaandcell lysateat
low temperature (4 °C) where endocytosis is
blocked. After 1-h incubation with human chondro-
cytes at 4 °C, ~25% of proMMP-13 was detected in
the cell lysate whereas only a small portion of
proMMP-13 was detected in the cell lysate after 1-h
incubation with the cells at 37 °C (Fig. 2D). The
increased distribution of proMMP-13 in the cell
Fig. 2. LRP1 is the primary endocytic receptor for MMP-13 in human normal chondrocytes. A, Confocal microscopy
analysis of proMMP-13 endocytosis by human normal chondrocytes. Cells were incubated with 20 nM proMMP-13 (FLAG
tag at N-terminus) in the presence or absence of 500 nM RAP for 1 h. Endocytosed proMMP-13, EEA1, cytoskeleton, and
nucleus were visualized as described under “Experimental procedures”. B and C, Human chondrocytes (n = 3
transfected with non-targeting siRNA (siCtrl) or LRP1 targeting siRNA (siLRP1) were cultured for 2 days in DMEM
containing 10% FCS. B, left panel, Representative Western blotting for LRP1 α-chain (515 kDa) and β-chain (85 kDa) in
cell lysate using anti-LRP1 α-chain (8G1) and β-chain (EPR3724) antibodies, respectively. Right panel, Densitometric
analysis of immunoreactive LRP1 bands detected was then carried out and the amount of LRP1 was expressed as a % o
the amount of LRP1 in untransfected cells (None). C, Human chondrocytes (n = 3) were further incubated with 10 nM
proMMP-13 in the absence or presence of 500 nMRAP for 0–4 h and proMMP-13 in the mediumwas detected byWestern
blotting using an MMP-13 specific antibody (H-230). Upper panel, Representative Western blotting. Lower panel
Densitometric analysis of immunoreactive proMMP-13 bands detected in the medium was carried out and the amount o
proMMP-13 was expressed as a % of the amount of proMMP-13 at 0 h. D, Human chondrocytes (n = 3) were incubated
with 10 nM proMMP-13 in the absence or presence of 500 nM RAP for 1 h at 37 °C or 4 °C, and proMMP-13 in the
medium and the cell lysate was detected as in C. Upper panel, Representative Western blotting. Lower panel
Densitometric analysis of immunoreactive proMMP-13 bands was carried out as in C. Bars and points represent the
means ± S.D. *, p b 0.05, **, p b 0.01; unpaired t test.





61Molecular basis behind MMP-13 endocytosislysate when cells were incubated at 4 °C was
abolished in the presence of RAP.
2.3. MMP-13 directly binds to LRP1 via its Hpx
domain
We then tested whether proMMP-13 directly binds
to LRP1 by a solid-phase binding assay.
ProMMP-13 expressed in HEK293 cells and proMM-
P-13(E223A) expressed in Escherichia coli bound to
immobilized LRP1 with very similar apparent binding
constant (KD,app) of 5.9 nM and 6.0 nM, respectively
(Fig.3A), whereas proMMP-1(E200A), and proMM-
P-3(E202A), both of which were expressed in E. coli,
showed much weaker binding affinities to LRP1. To
determine which domain(s) of MMP-13 is responsi-
ble for the binding to LRP1, activated forms of
MMP-13(E223A) and HpxMMP-13 were analysed.
Both MMP-13 and HpxMMP-13 bound to immobilized
LRP1 with KD,app values of 3.8 nM and 2.7 nM,
respectively (Fig. 3C and Table 1), suggesting that
HpxMMP-13 is essential for the interaction with LRP1.
To further investigate the role of the Hpx domain in
the interaction with LRP1, we constructed MMP
chimeras consisting of the catalytic and hinge
domains of MMP-13 and the Hpx domain of
MMP-1 (MMP-13-13-1(E223A)), or the catalytic
and hinge domains of MMP-1 and the Hpx domain
of MMP-13 (MMP-1-1-13(E200A)) (Fig. 3B).
MMP-1-1-13 bound to immobilized LRP1 with similar
affinity to that of MMP-13 (KD,app = 5.1 nM) (Fig.
3C). Furthermore, competition studies on the
MMP-13 binding to LRP1 showed that the addition
of neither MMP-1 nor MMP-13-13-1 inhibits the
MMP-13 binding to LRP1, whereas HpxMMP-13 and
MMP-1-1-13 similarly inhibited the binding in a
dose-dependent manner (Fig. 3D), supporting our
conclusion described above. We further investigated
the role of HpxMMP-13 on MMP-13 endocytosis by
human chondrocytes. Cultured chondrocytes endo-
cytosed HpxMMP-13 rapidly with half-life of approx.
50 min (Fig. 3E). Furthermore, cellular uptake of
proMMP-13 was competitively inhibited by addition
of excess amount of HpxMMP-13 (Fig. 3F).2.4. Effect of heparin on the binding of MMP-13
to LRP1
Heparin binds to ADAMTS-4, -5 [47,48] and
TIMP-3 [49], and inhibits endocytosis of these
molecules [40,41,49]. It has been reported that
MMP-13 also binds to heparin [50]. We found that
proMMP-13, MMP-13 and HpxMMP-13 bind to immo-
bilized heparin with KD,app of 12 nM, 34 nM and
79 nM, respectively (Fig. 4A and Table 1). We thus
examined the effect of heparin on the binding of
MMP-13 to LRP1. The binding of proMM-
P-13(E223A) and MMP-13(E223A), and HpxMMP-13was inhibited by heparin in a dose-dependent
manner with concentrations of heparin that inhibit
50% binding of 2.1 μg/ml, 18 μg/ml and 145 μg/ml,
respectively (Fig. 4B). We further investigated the
effect of heparin on MMP-13 endocytosis in human
chondrocytes. Cellular uptake of proMMP-13,
MMP-13 and HpxMMP-13 was almost completely
inhibited in the presence of heparin (Fig. 4C).
2.5. Binding of MMP-13 to LRP1 ligand binding
clusters
The ligand binding regions in LRP1 occur in four
clusters (clusters I–IV) containing between 2 and 11
individual ligand-binding cysteine-rich repeats
(Fig. 5A). To identify the region(s) of LRP1 that binds
to MMP-13, each recombinant cluster was coated on
multi-well plates and subsequent binding of MMP-13
was quantified. ProMMP-13(E223A) bound to immo-
bilized clusters II and III with high affinity, with KD,app
values of 17 nM and 24 nM, respectively (Fig. 5B and
Table 2). Likewise, HpxMMP-13 bound to immobilized
clusters II and III with high affinity, withKD,app values of
15 nM and 13 nM, respectively (Fig. 5C and Table 2).
2.6. MMP-13 does not inhibit the interaction
between LRP1 and ADAMTS-4 or -5, or TIMP-3
To investigate the selectivity of MMP-13 binding
sites on LRP1, competition studies were carried out
on proMMP-13(E223A) binding to LRP1. The addi-
tion of ADAMTS-4, -5, or TIMP-3 did not inhibit
proMMP-13 binding to LRP1 (Fig. 6A). ProMMP-13
bound to immobilized LRP1 in the presence of
50 nM ADAMTS-5, 250 nM ADAMTS-4 or 50 nM
TIMP-3 with KD,app of 5.2 nM, 5.6 nM and 8.2 nM,
respectively (Fig. 6B).
We previously found that ADAMTS-5 binds to
clusters II and IV with high affinity, with KD,app values
of 3.5 and 9 nM, respectively [40]. We also found
that TIMP-3 binds to cluster II with high affinity
(unpublished observation). To further investigate
whether MMP-13 and ADAMTS-5 or TIMP-3 bind
to different regions of cluster II, we carried out
competition studies on the binding of these proteins.
The addition of ADAMTS-5 did not markedly affect
the proMMP-13(E223A) binding to cluster II, or vice
versa (Fig. 6C and D). The addition of TIMP-3 slightly
inhibited proMMP-13 binding to cluster II (Fig. 6C),
whereas the addition of proMMP-13 slightly in-
creased TIMP-3 binding to cluster II (Fig. 6E).2.7. Co-endocytosis of MMP-13 and ADAMTS-5
or TIMP-3 in human chondrocytes
To examine whether MMP-13 competitively in-
hibits the endocytosis of other molecules such as
ADAMTS-5 or TIMP-3, 10 nM ADAMTS-5 or 10 nM
62 Molecular basis behind MMP-13 endocytosisTIMP-3 was incubated with human chondrocytes in
the presence of 10-fold molar excess of proMM-
P-13(E223A), and the level of these proteins in the
medium was monitored by Western blot analysis.
The addition of 100 nM proMMP-13 did not affect
the rate of ADAMTS-5 endocytosis (Fig. 7A),
whereas the addition of 100 nM proMMP-13 slightly
increased the rate of TIMP-3 endocytosis (Fig. 7B).
To further test whether MMP-13 endocytosis is
competed by ADAMTS-5 or TIMP-3, reverse com-petition studies were carried out. The addition of
100 nM ADAMTS-5 did not affect the rate of
proMMP-13 endocytosis, whereas the addition of
100 nM TIMP-3 slightly reduced the rate of endocy-
tosis (Fig. 7C). We then examined endocytosis of
exogenously added proMMP-13(E223A) and
ADAMTS-5 (FLAG tag at C-terminus) or TIMP-3
(FLAG tag at C-terminus) by immunofluorescent
confocal microscopy. Punctate staining of proMMP-13,
ADAMTS-5 and TIMP-3 was observed within cells and
63Molecular basis behind MMP-13 endocytosismost proMMP-13 signals colocalizedwith the signals of
ADAMTS-5 or TIMP-3 (Fig. 7D).3. Discussion
In this study, we have demonstrated that LRP1 is
the major endocytic receptor of MMP-13 in human
chondrocytes and that it directly binds to MMP-13,
mediating its internalization for subsequent lysosomal
degradation. This was supported by experiments in
which the addition of RAP or gene silencing of LRP1
markedly inhibited the cellular uptake of proMMP-13
fromculturemedia, and by an increased accumulation
of proMMP-13 in the cell lysate at lower temperature
(4 °C), in a RAP-sensitive manner.
We then identified that the LRP1 binding site of
MMP-13 is located solely in the HpxMMP-13 domain.
Little contribution to LRP1 binding was made by either
the pro-domain or the catalytic domain, since the
binding constants of HpxMMP-13 were lower than those
of proMMP-13 and the activated form of MMP-13. This
finding was unexpected, because MMP-13 has a large
positively charged area extending over both the
catalytic and in Hpx domains located on the opposite
site of the collagen-binding sites [51].We predicted that
these basic residues are most likely involved in the
interaction with LRP1, as has been shown for many
LRP1 ligands [37]. These residues are also candidates
for the binding to heparin and highly sulfated proteo-
glycans, which interfere the interaction between LRP1
and its ligands, for example, as has been shown for
ADAMTS-4 [40], ADAMTS-5 [41], TIMP-3 [42,49] and
for MMP-13 in this study. However, proMMP-13,
MMP-13 and HpxMMP-13 bind to heparin with different
affinities: theKD,app value for proMMP-13 is 5-fold lower
than that of HpxMMP-13, and the inhibitory effect of
heparin on proMMP-13 binding to LRP1 is about
70-fold more potent than that for HpxMMP-13. These
differences are probably due to the fact that heparin
binds to a more extended area of positively charged
residues in the proMMP-13 molecule, but the LRP1Fig. 3. MMP-13 directly binds to LRP1 via its Hpx domain.
binding of proMMP-1(E200A), proMMP-3(E202A), proMMP
measured using anti-MMP-1 (SB12e), MMP-3 (4B7.3) and
horseradish peroxidase-conjugate secondary antibody as de
representation of MMP-13, its domain deletion mutant and MM
domain, a hinge and a Hpx domain from MMP-13 and MMP-
MMP-1 sequence as light grey. Pro, pro-domain; Cat, cata
Full-length LRP1 was coated onto microtiter plates and binding
of MMP-13 (HpxMMP-13) and proMMP-1-1-13(E200A) (each 0
coated onto microtiter plates and binding of 6 nM proMM
P-13-13-1(E223A), proMMP-1-1-13(E200A) or proMMP-1(E20
M2 antibody. The amount of proMMP-13 bound to LRP1 was
LRP1 in the absence of the competitor. E, Human chondroc
absence or presence of 500 nM RAP for 0–4 h, and HpxMMP-1
Human chondrocytes (n = 3) were incubated with 10 nM pro
HpxMMP-13 or 500 nM RAP for 0–4 h, and proMMP-13 rema
represent the means ± S.D.binding site is more restricted and localized in the Hpx
domain.
There are four ligand-binding clusters in LRP1
(clusters I–IV), each harbouring multiple ligand-bind-
ing repeats. Of the LRP1 ligands whose binding sites
in LRP1 have been mapped, most of them interact
with clusters II and IV [52]. We previously reported
that both ADAMTS-4 and -5 bind to clusters II and IV,
and showed that ADAMTS-5 is an effective compet-
itive inhibitor of ADAMTS-4 binding to LRP1 as the
former has a higher affinity for LRP1 than the latter
[40]. These results suggested that these two
proteinases share the same binding site on LRP1.
In this study, we found that MMP-13 binds to clusters
II and III. To date, only four other LRP1 ligands, RAP
[53], apolipoprotein E [54], thrombin-protease nexin
1 complex [55], and blood coagulation factor VIII [56]
are known to bind to cluster III. Furthermore, we
have shown that proMMP-13 does not interfere with
the binding of ADAMTS-4 or -5 to LRP1, even
though it has high affinity binding constants in the
range of 2.7–6.0 nM. This indicates that MMP-13
and ADAMTS-4/-5 bind different sites within cluster
II. TIMP-3 also binds to cluster II. Interestingly, the
binding affinity of proMMP-13 for LRP1 was slightly
reduced in the presence of TIMP-3, whereas TIMP-3
binding affinity to LRP1 was slightly increased in the
presence of proMMP-13. Consistent with these obser-
vations, the rate of TIMP-3 endocytosis was slightly
increased in the presence of proMMP-13, and the rate
of proMMP-13 endocytosis was slightly reduced in the
presence of TIMP-3. This suggests that proMMP-13
and TIMP-3 bind to different sites on LRP1 but their
binding to LRP1 affects the other binding sites
allosterically. The distinct binding sites for MMP-13
and for TIMP-3 or ADAMTS-5 on LRP1 are further
supported by the co-internalization of proMMP-13 and
ADAMTS-5 or TIMP-3 by chondrocytes. Thus, the rate
of proMMP-13 endocytosis cannot be greatly altered
even when the concentrations of ADAMTS-4, -5 and
TIMP-3 are elevated. Once activated,MMP-13 forms a
catalytically inactive complex with TIMP-3 [9]. In thisA, Full-length LRP1 was coated onto microtiter plates and
-13(WT) and proMMP-13(E223A) (each 0–50 nM) was
MMP-13 (181-14G11) antibodies, respectively, and a
scribed under “Experimental procedures”. B, Schematic
P-13/MMP-1 chimeras made by combination of a catalytic
1. The MMP-13 sequence is shown as dark grey and the
lytic domain; Hinge, hinge region; Hpx, Hpx domain. C,
of proMMP-13(E223A), MMP-13(E223A), the Hpx domain
–50 nM) was measured as in A. D, Full-length LRP1 was
P-13(E223A) in the presence of HpxMMP-13, proMM-
0A) (each 0–200 nM) was measured using an anti-FLAG
expressed as a % of the amount of proMMP-13 bound to
ytes (n = 3) were incubated with 10 nM HpxMMP-13 in the
3 remaining in the medium was measured as in Fig. 3C. F,
MMP-13(E223A) in the absence or presence of 500 nM
ining in the medium was measured as in Fig. 2C. Points
Table 1. KD,app values for binding of proMMP-13, MMP-13,
HpxMMP-13 to LRP1 and heparin.
KD,app values (nM) were estimated based on the results in Figs. 3
and 4.
ProMMP-13 MMP-13 HpxMMP-13
LRP1 6.0 3.8 2.7
Heparin 12 34 79
Fig. 4. Effect of heparin and type I collagen on the binding
binding microtiter plates and the binding of proMMP-13(E223A
measured using anti-MMP-13 (181-14G11) antibody, and a h
described under “Experimental procedures”. B, Full-length LR
proMMP-13(E223A), MMP-13(E223A) and HpxMMP-13 (each
measured as in Fig. 3A. C, Human chondrocytes (n = 3) were
HpxMMP-13 (each 10 nM) in the absence or presence of 500 μ
medium was measured as in Fig. 2C. Points represent the me
64 Molecular basis behind MMP-13 endocytosiscase, the Hpx domain of MMP-13 is likely to be outside
of the interface of MMP-13 and TIMP-3, and the
complex can be endocytosed through both the
MMP-13 and TIMP-3 binding sites.
Efficient clearance of MMP-13 by chondrocytes
from the extracellular space would explain the
generally accepted view that MMP-13 is not produced
in most adult human tissues in the steady state. This
study has, however, revealed that human chondro-
cytes isolated from healthy adults constitutivelyof MMP-13 to LRP1. A, Heparin was coated onto heparin
), MMP-13(E223A) and HpxMMP-13 (each 0–540 nM) was
orseradish peroxidase-conjugate secondary antibody as
P1 was coated onto microtiter plates and the binding of
3 nM) in the presence of heparin (0–500 μg/ml) was
incubated with proMMP-13(E223A), MMP-13(E223A) and
g/ml heparin for 0–4 h, and each protein remaining in the
ans ± S.D.
Table 2. KD,app values for binding of proMMP-13,
HpxMMP-13, ADAMTS-4 and -5 to LRP1 and its fragments.
Extrapolated KD,app values (nM) were estimated based on the











ProMMP-13 6.0 N200 17 24 N100
HpxMMP-13 2.7 N200 15 13 N50
ADAMTS-4 110 N1000 240 N500 330
ADAMTS-5 3.8 N200 3.5 41 9
Fig. 5. Binding of MMP-13 to LRP1 ligand binding clusters. A, Modular domain organization of LRP1 and its soluble
receptor fragments used in this study. The four clusters of ligand-binding clusters are numbered I–IV. The symbols for the
various domains are indicated in the inset. B and C, Purified LRP1 fragments (clusters I to IV) were coated onto microtiter
plates, and the binding of proMMP-13(E223A) (B) or HpxMMP-13 (C) (each 0–200 nM) was measured as in Fig. 4A.
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rapidly endocytosed and degraded by chondrocytes.
It is therefore difficult to detect proMMP-13 in the
condition medium unless the endocytic pathway is
blocked by RAP. Similarly, it is also difficult to detect
protein levels of ADAMTS-5 [57] and TIMP-3 [42] in
the medium of cultured chondrocytes, even though
their mRNAs are present, until their endocytosis is
blocked by RAP. We speculate that these molecules
including MMP-13, only function for a finite period of
time in the turnover of ECM proteins in normal steady
state tissues, in order to avoid over-degradation of the
cartilage ECM. This also suggests that impairment of
the LRP1-mediated endocytosis can disrupt normal
tissue homeostasis.
Overexpression of MMP-13 has been observed
under numerous pathologic conditions that are
characterized by the destruction of collagenous
tissue architecture, e.g., in chronic cutaneous ulcers
[58], chronic periodontitis [59], atherosclerosis [60],
aortic aneurysms [61] and rheumatoid arthritis [62].
The expression of MMP-13 mRNA and its protein
levels in cartilage correlate with the progression of
OA in humans [23]. Treatment with inflammatory
cytokines stimulates MMP-13 expression in human
chondrocytes [63]. We previously reported that
LRP1-mediated endocytosis is impaired in OA
cartilage due to a loss in LRP1 protein without
significant changes in its mRNA [41]. A similar
impairment of MMP-13 endocytosis was also report-
ed [33]. We therefore proposed that the ectodomainof LRP1 is shed from the cell surface of OA
chondrocytes, thereby reducing the endocytic ca-
pacity of the cell. Under inflammatory conditions
such as in rheumatoid arthritis and systemic lupus
erythematosus, MMP-13 transcription is elevated,
and LRP1 shedding is also increased [63,64]. The
shedding of LRP1 is also enhanced in chondrocytes
treated with interleukin 1 via activation of c-jun
N-terminal kinase-2 signalling pathway [65]. Thus,
an increased shedding of LRP1 along with increased
expression of MMP-13 enhances the degradation
collagen fibrils in cartilage. Since LRP1 endocytoses
not only matrix-degrading proteinases and their
inhibitors, but also numerous biologically active
factors such as CCN2, transforming growth factor-β,
and complement 3C [37], the shedding of LRP1
results in significant alteration of tissue environ-
ments and cellular behaviour. We are currently
investigating proteinases responsible for the
Fig. 6. MMP-13 does not inhibit interaction between LRP1 and ADAMTS-4 or -5, or TIMP-3. A, Full-length LRP1 was
coated onto microtiter plates and binding of 6 nM proMMP-13(E223A) in the presence of ADAMTS-5, TIMP-3 or RAP
(each 0–100 nM), or ADAMTS-4 (0–500 nM) plus 50 μM CT1746 was measured as in Fig. 3A. The metalloproteinase
inhibitor CT1746 was added to block autodegradation of ADAMTSs. The amount of proMMP-13 bound to LRP1 was
expressed as a % of the amount of proMMP-13 bound to LRP1 in the absence of the competitor. B, Full-length LRP1 was
coated onto microtiter plates and the binding of proMMP-13(E223A) (0–40 nM) in the absence or presence of 50 nM
ADAMTS-5, 250 nM ADAMTS-4 or 50 nM TIMP-3 plus 50 μM CT1746 was measured as in Fig. 3A. C, Purified cluster II
was coated onto microtiter plates, and the binding of 20 nM proMMP-13(E223A) in the presence of ADAMTS-5, TIMP-3 or
RAP (each 0–100 nM) plus 50 μM CT1746 was measured as in Fig. 3D. D and E, Purified cluster II was coated onto
microtiter plates, and the binding of 5 nM ADAMTS-5 (D) or 5 nM TIMP-3 (E) in the presence of proMMP-13(E223A) or
RAP (each 0–100 nM) plus 50 μM CT1746 was measured as in Fig. 3D using anti-FLAG M2 antibody, and a horseradish
peroxidase-conjugate secondary antibody as described under “Experimental procedures”. The amount of ADAMTS-5 or
TIMP-3 bound to the cluster II was expressed as a % of the amount of ADAMTS-5 or TIMP-3 bound to the cluster II in the
absence of the competitor.
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67Molecular basis behind MMP-13 endocytosisshedding of LRP1 in cartilage as we think they play a
key role in initiating a shift of normal chondrocytes to
a pathological phase. Identification of such shed-
dase(s) may help us to develop a new way to control
the progression of OA.4. Experimental procedures
4.1. Reagents and antibodies
The sources of materials used were as follows: the
anti-FLAG M2 mouse monoclonal antibody and
heparin from Sigma (Dorset, UK); the anti-EEA1
rabbit polyclonal antibody, the anti-LRP1 α-chain
mouse monoclonal antibody 8G1, the anti-LRP1
β-chain rabbit monoclonal antibody EPR3724, the
anti-MMP-1 mouse monoclonal antibody SB12e,
and the anti-MMP-3 mouse monoclonal antibody
4B7.3 from Abcam (Cambridge, UK); the
anti-MMP-13 Hpx domain mouse monoclonal anti-
body 181-14G11 from Merck Millipore (Darmstadt,
Germany); the anti-MMP-13 rabbit polyclonal anti-
body H-230 from Santa Cruz (Dallas, TX); a
hydroxamate-based MMP inhibitor CT-1746
(N1-[2-(S)-(3,3-dimethylbutanamidyl)]-N4-hydrox-
y-2-(R)-[3-(4-chlorophenyl)-propyl]-succinamide) from
UCB Celltech (Slough, UK); a hydroxamate-based
MMP inhibitor GM6001 (N-[(2R)-2-(hydroxamidocar-
bonylmethyl)-4-methylpentanoyl]-L-tryptophan methy-
lamide) fromElastin Product (Owensville, MO); purified
human full-length LRP1 from BioMac (Leipzig, Germa-
ny). The anti-human ADAMTS-5 catalytic domain
rabbit polyclonal antibody was raised in rabbits and
charac ter ized [66 ] . Recombinant human
MMP-1(E200A), MMP-3(E202A) [67], MMP-13 with a
FLAG tag between the signal and propeptide [68],
MMP-13(E223A) [51], ADAMTS-4 lacking C-terminus
spacer domain [69], ADAMTS-5 lacking C-terminus
thrombospondin domain [66], TIMP-3 [70], RAP [41],
and the LRP1 ligand-binding clusters I–IV [40] were
prepared as described previously. All other reagents
used were of the highest analytical grade available.
4.2. Human cartilage tissue preparation and
isolation of chondrocytes
Healthy (normal) articular cartilage was obtained
from the Stanmore BioBank, Institute of Orthopae-
dics, Royal National Orthopaedic Hospital, Stan-
more from patients following informed consent and
approval by the Royal Veterinary College Ethics and
Welfare Committee (Institutional approval URN 2010
0004H). Articular cartilage was obtained from the
femoral condyles of the knee following amputation
due to soft tissue sarcoma and osteosarcoma with
no involvement of the cartilage. Tissues were
obtained from 5 patients (3 males aged 18, 23 and57 years; 2 females aged 19 and 68 years). Chon-
drocytes were isolated as described previously [42].
Both primary and passaged human cells were used
in the experiments.
4.3. Detection of endogenous MMP-13 in human
normal chondrocytes
Cells cultured on 6-well plate were incubated in
2 ml of DMEM with or without 500 nM RAP at 37 °C
for 0–8 h. The protein in media was precipitated with
TCA and dissolved in 20 μl of 1× SDS-sample buffer
(50 mM Tris-HCl pH 6.8, 5% 2-mercaptoethanol, 2%
SDS and 10% glycerol). The cells were washed with
DMEM and lysed in 200 μl of 2× SDS-sample buffer.
All samples and various amounts of purified MMP-13
were analysed simultaneously by SDS-PAGE and
Western blotting using an MMP-13 specific antibody
(H-230). Immunoreactive bands were quantified
using ImageJ and the amount of endogenous
MMP-13 was determined in comparison with purified
MMP-13 within its reasonable linear range.
4.4. Quantitative reverse transcriptase-PCR
Quantitative reverse transcriptase-PCR was carried
out as described previously [41]. Briefly, cDNA was
generated using a reverse-transcription kit (Applied
Biosystems, Foster City, CA, USA) and random
primers from RNA extracted and prepared using the
RNeasymini kit (Qiagen, Valencia, CA, USA) following
themanufacturer's guidelines. cDNAwas then used for
real time PCR assays using TaqMan technology. The
ΔΔ threshold cycle (ΔΔCt) method of relative quanti-
tation was used to calculate relative mRNA levels for
each transcript examined. The 60S acidic ribosomal
protein P0 (RPLP0) gene was used to normalize the
data. Pre-developed primer/probe sets for MMP-13
and RPLP0 were purchased from Applied Biosystems.
4.5. Generation of MMP-1/MMP-13 chimera
mutants
The constructs of MMP-1/MMP-13 chimeras are
shown in Fig. 3B. MMP-1 was cloned into a pET3a
expression vector and MMP-1/MMP-13 chimeras
were constructed with the overlapping PCR as
described previously [71]. MMP-13-13-1(E223A)
(MMP-131-263-MMP-1259-450) using a sense primer
(5′-TCATTGTCGGCATATGCCCCTTCCC-3′) and
an antisense primer (5′-ATCAAAGGTTAGCT-
TACTGTCACATTTGTCTGGCGTTTTTGG-3′) with
MMP-13 cDNA in pGEM-T vector as template, and
a sense primer (5′-AAACATCCAAAAACGCCAGA-
CAAATGTGACAGTAAGCTAACC-3′) and an anti-
sense primer (5 ′-GCTTTGTTAGCAGCCGG
ATCC-3′) with MMP-1 in pET3a as a template.
Both PCR fragments were combined in an overlap
ex t ens i on PCR us i ng a sense p r ime r
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an antisense primer (5′-GCTTTGTTAGCAGCCG-
GATCC-3′) 13-UF/pET3a-R, the resulting fragment
was cloned into pET3a. MMP-1-1-13(E200A)
(MMP-11-258-MMP-13264-451) was made using the
same method. In short, MMP-1-1-13 construction
first the internal NdeI site in the hemopexin domain of
MMP-13 was engineered out (CATATG → CC-TATG). This MMP-13 construct was then used as
a template for PCR with a sense primer
(5′-CCAAAAGCGTGTGACCCTTCC-3′) and an an-
tisense primer (5 ′-GCTTTGTTAGCAGCCG-
GATCC-3′). A sense primer (5′-TAATACGACT
CACTATAGGG-3′) and an antisense primer
(5′-GATAAGGAAGGGTCACACGCTTTTGGGG-3′)
were used with MMP-1 as a template.




expressed, refolded from inclusion bodies and purified
as described [71]. ProMMP-13-13-1(E223A) was
purified with modifications. After the addition of
isopropyl β-D-thiogalactopyranoside, cell culture was
continued at room temperature for 5 h. For folding
dialysis buffer was 1 mM ZnCl2 and 50 mM Tris-ace-
tate (pH 5.5) instead of 50 mM Tris-HCl (pH 7.5) to
prevent autolysis. After refolding, samples were
applied to an S-column instead of a Green A column
equilibrated with 50 mM sodium acetate (pH 5.5),
1 mMZnCl2, 10 mMCaCl2, and 0.02%NaN3. As final
purif ication step, Sephacryl S-200 column
(2.5 × 45 cm) was run using the same buffer.
Expression of chimeras using pCEP4/HEK293-EBNA
system was essential as described previously [72].
These proteins were detected in the medium, and
conditioned medium was harvested twice weekly and
the proteins were purified using the method described
previously but without Brij-35. The FLAG peptide was
removed by gel filtration of Sephacryl S200 equilibrat-
ed with Tris-buffered saline (TBS) containing 10 mM
CaCl2 (TNC) and 0.02% NaN3. The hemopexin
domain of MMP-13 (HpxMMP-13) was made by
incubating proMMP-13 with 1 mM APMA at 37 °C
for at least 16 h. The protein was run over a Green A
column to remove the full-length MMP-13 and the
catalytic domain of MMP-13, and the unbound
material containing the HpxMMP-13 was collected.
4.7. Immunocytochemical localization of MMP-
13, ADAMTS-5 and TIMP-3
Cultured cells on 4-well Lab-Tek chamber slides
(Nunc, Roskilde, Denmark) were incubated in DMEM
with 20 nM proMMP-13 (with a FLAG tag at N-termi-
nus) in the absence or presence of 500 nMRAP for 1 h
at 37 °C. Cells were washedwith DMEM, fixedwith 3%
paraformaldehyde in TNC containing 0.1% Triton
X-100 (15 min, room temperature). Each sample was
incubated with anti-FLAG M2 mouse monoclonal
antibody and anti-EEA1 rabbit polyclonal antibody
(3 h, room temperature). Alexa Fluor 488-conjugatedFig. 7. Co-endocytosis of MMP-13 and ADAMTS-5 or TIMP
(n = 3) were incubated with 10 nM ADAMTS-5 (FLAG tag at C
(B) plus 10 μM CT1746 in the absence or presence of 100
ADAMTS-5 (A) or TIMP-3 (B) remaining in the medium was m
Human chondrocytes (n = 3) were incubated with 10 nM pro
presence of 100 nM ADAMTS-5, 100 nM TIMP-3 or 500 nMRA
measured as in Fig. 2C. Points represent the means ± S.D. D,
and TIMP-3 endocytosis by human normal chondrocytes. C
10 nM ADAMTS-5 or 10 nM TIMP-3 plus 10 μMCT1746 in the
proMMP-13, ADAMTS-5 and TIMP-3 were visualized using
anti-FLAG M2 mouse monoclonal antibody as described undeanti-mouse IgG and Alexa Fluor 568-conjugated
anti-rabbit IgG (Molecular Probes, Eugene, OR) were
used to visualize the antigen signals (1 h, room
temperature). Actin was stained with Actin-stain 670
phalloidin (Cell Signaling) and nuclei were stained with
DAPI. Samples were viewed using a Nikon Eclipse
TE2000-U confocal laser scanning microscope. The
datawere collatedusingVolocity software (Improvision,
Coventry, UK). For co-endocytosis analysis, cultured
cells on 4-well Lab-Tek chamber slides were incubated
in DMEM containing 10 nM proMMP-13 with or without
10 nM ADAMTS-5 or 10 nM TIMP-3 in the absence or
presenceof 500 nMRAP for 1 hat 37 °C.Eachsample
was incubated with anti-MMP-13 rabbit polyclonal
antibody (H-230) and anti-FLAG M2 mouse monoclo-
nal antibody (3 h, room temperature). Endocytosed
proMMP-13, ADAMTS-5 and TIMP-3, cytoskeleton,
and nucleus were visualized as described above.
4.8. siRNA knockdown of LRP1 in human
articular chondrocytes
siRNA oligonucleotides for LRP1 (On-TargetPlus
SMARTpool siRNA) and nontargeting oligonucleo-
tide were purchased from Thermo Scientific Dhar-
macon (Lafayet te, CO). Human art icular
chondrocytes were plated at a density of 3.5 × 104
cells/well (24-well plate) in DMEM containing 10%
FCS and incubated until 50% confluent. INTER-
FERin (peqlab, Erlangen, Germany) was used to
transfect cells with siRNA at a final concentration of
10 nM in Opti-MEM I. At 4 h after transfection, the
Opti-MEM was removed and replaced with DMEM
containing 10% FCS.
4.9. Analysis of endocytic clearance of recombi-
nant proteins
Cells cultured on 24-well plate were incubated in
500 μl of DMEM containing 10 nM of each recom-
binant protein with or without 500 nM RAP at 37 °C.
After incubation for various periods of time, media
were collected and the protein was precipitated with
TCA and dissolved in 50 μl of 1× SDS-sample buffer
(50 mM Tris-HCl pH 6.8, 5% 2-mercaptoethanol, 2%
SDS and 10% glycerol). All samples were analysed
by SDS-PAGE and Western blotting using specific-3 in human chondrocytes. A and B, Human chondrocytes
-terminus) (A) or 10 nM TIMP-3 (FLAG tag at C-terminus)
nM proMMP-13(E223A) or 500 nM RAP for 0–4 h, and
easured as in Fig. 2C using an anti-FLAG M2 antibody. C,
MMP-13(E223A) plus 10 μM CT1746 in the absence or
P for 0–4 h, and proMMP-13 remaining in the medium was
Confocal microscopy analysis of proMMP-13, ADAMTS-5
ells were incubated with 10 nM proMMP-13(E223A) and
absence or presence of 500 nM RAP for 1 h. Endocytosed
with anti-MMP-13 rabbit polyclonal antibody (H-230) and
r “Experimental procedures”.
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noreactive bands were quantified using ImageJ and
the amount of each recombinant protein remaining in
the medium at each time point was calculated as a
percentage of the amount of each recombinant
protein at 0 h.
4.10. ELISA for binding of recombinant proteins
to LRP1, soluble LRP1 fragments or heparin
Human full-length LRP1 or soluble LRP1 cluster II
(5 nM or 25 nM, respectively, in 100 μl of TNC) was
coated overnight at 4 °C onto microtiter plates
(Corning, NY). Wells were blocked with 3% BSA in
TNC (1 h; 37 °C) and washed in TNC containing
0.05% Brij-35 after this and each subsequent step.
Wells were then incubated with various concentra-
tions of recombinant proteins in blocking solution for
3 h at room temperature. Bound proteins were
detected using each recombinant protein specific
antibody (1 h; room temperature) and then with a
secondary antibody coupled to horseradish peroxi-
dase (1 h; room temperature). Hydrolysis of tetra-
methylbenzidine substrate (KPL, Gaithersburg, MA)
was measured at 450 nm using a FLUOstar Omega
(BMG Labtech). Each value was normalized by
subtracting the amount of recombinant protein
bound to control the well that was not coated with
LRP1 or soluble LRP1 fragments.
For the heparin-binding assay, heparin (10 μg/ml
in 100 μl of TNC) was coated overnight at 4 °C onto
heparin-binding plates (BD Life Sciences). Wells
were blocked with 0.2% (m/v) gelatin in TNC (1 h;
37 °C) and washed in TNC containing 0.05% Brij-35
after this and each subsequent step. Wells were then
incubated with various concentrations of recombi-
nant proteins in blocking solution for 3 h at room
temperature. Bound proteins were detected using
ant i -MMP-13 mouse monoclonal ant ibody
181-14G11 (1 h; room temperature) and then with
a secondary antibody coupled to horseradish per-
oxidase (1 h; room temperature). Hydrolysis of
tetramethylbenzidine substrate (KPL, Gaithersburg,
MA) was measured as described above.Author contribution
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